Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterolane-piperaquine vs DHA-piperaquine for Uncomplicated Falciparum Malaria in Myanmar
NCT02461186Phase 3Withdrawn
- Sponsor
- University of Oxford
- Start
- Jun 2015
- Primary completion
- Jun 2017
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
Phase 3, randomised, open-label trial of Arterolane in Malaria (2 arms), sponsored by University of Oxford. Primary endpoint: Peripheral blood parasite half-life at 2 years. Planned start Jun 2015; status: withdrawn.
02
Drugs
Arterolane
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT02461186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461186.